OSRH Key Statistics, Chart & Performance
The current stock price of OSRH is 0.662 USD. In the past month the price increased by 2%.
OSRH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About OSRH
Company Profile
OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.
Company Info
OSR HOLDINGS INC
10900 Ne 4Th Street, Suite 2300
Bellevue WASHINGTON US
Employees: 0
Phone: 14256357700
OSR HOLDINGS INC / OSRH FAQ
Can you describe the business of OSR HOLDINGS INC?
OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.
What is the current price of OSRH stock?
The current stock price of OSRH is 0.662 USD. The price increased by 6.43% in the last trading session.
What is the dividend status of OSR HOLDINGS INC?
OSRH does not pay a dividend.
What is the ChartMill technical and fundamental rating of OSRH stock?
OSRH has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is OSR HOLDINGS INC (OSRH) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OSRH.
What is OSR HOLDINGS INC worth?
OSR HOLDINGS INC (OSRH) has a market capitalization of 16.99M USD. This makes OSRH a Nano Cap stock.
What is the next earnings date for OSRH stock?
OSR HOLDINGS INC (OSRH) will report earnings on 2026-04-17.
OSRH Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to OSRH.
OSRH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OSRH. OSRH has a bad profitability rating. Also its financial health evaluation is rather negative.
OSRH Financial Highlights
Over the last trailing twelve months OSRH reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS decreased by -253.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.58% | ||
| ROE | -18.56% | ||
| Debt/Equity | 0.05 |
OSRH Forecast & Estimates
7 analysts have analysed OSRH and the average price target is 10.2 USD. This implies a price increase of 1440.79% is expected in the next year compared to the current price of 0.662.